362 related articles for article (PubMed ID: 30580005)
1. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
[TBL] [Abstract][Full Text] [Related]
2. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
3. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
4. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
7. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
[TBL] [Abstract][Full Text] [Related]
8. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
9. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
[TBL] [Abstract][Full Text] [Related]
10. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
11. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population.
Cuocolo R; Stanzione A; Rusconi G; Petretta M; Ponsiglione A; Fusco F; Longo N; Persico F; Cocozza S; Brunetti A; Imbriaco M
Eur J Radiol; 2018 Jul; 104():64-70. PubMed ID: 29857868
[TBL] [Abstract][Full Text] [Related]
12. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer.
Wang R; Wang H; Zhao C; Hu J; Jiang Y; Tong Y; Liu T; Huang R; Wang X
PLoS One; 2015; 10(6):e0130207. PubMed ID: 26067423
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
Stevens E; Truong M; Bullen JA; Ward RD; Purysko AS; Klein EA
Urol Oncol; 2020 Nov; 38(11):846.e9-846.e16. PubMed ID: 32576527
[TBL] [Abstract][Full Text] [Related]
15. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
[TBL] [Abstract][Full Text] [Related]
16. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting.
Shah PH; Patel VR; Moreira DM; George AK; Alom M; Kozel Z; Joshi V; Ben-Levi E; Villani R; Yaskiv O; Kavoussi LR; Vira M; Olsson CO; Rastinehad AR
BJU Int; 2019 Feb; 123(2):239-245. PubMed ID: 30113138
[TBL] [Abstract][Full Text] [Related]
17. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
Chiu PK; Leow JJ; Chiang CH; Mok A; Zhang K; Hsieh PF; Zhu Y; Lam W; Tsang WC; Fan YH; Lin TP; Chan TY; Leung CH; Teoh JY; Chu PS; Zhu G; Ye DW; Wu HC; Tan TW; Tsu JH; Ng CF; Chiong E; Huang CY
J Urol; 2023 Jul; 210(1):88-98. PubMed ID: 37036248
[TBL] [Abstract][Full Text] [Related]
18. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
[TBL] [Abstract][Full Text] [Related]
19. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
